Advertisement
Australia markets close in 1 hour 30 minutes
  • ALL ORDS

    7,841.40
    -168.00 (-2.10%)
     
  • ASX 200

    7,590.20
    -162.30 (-2.09%)
     
  • AUD/USD

    0.6420
    -0.0025 (-0.39%)
     
  • OIL

    85.88
    +0.47 (+0.55%)
     
  • GOLD

    2,401.80
    +18.80 (+0.79%)
     
  • Bitcoin AUD

    97,370.17
    -3,788.29 (-3.74%)
     
  • CMC Crypto 200

    885.54
    0.00 (0.00%)
     
  • AUD/EUR

    0.6046
    -0.0013 (-0.22%)
     
  • AUD/NZD

    1.0910
    +0.0001 (+0.01%)
     
  • NZX 50

    11,803.28
    -113.50 (-0.95%)
     
  • NASDAQ

    17,706.83
    -296.65 (-1.65%)
     
  • FTSE

    7,965.53
    -30.05 (-0.38%)
     
  • Dow Jones

    37,735.11
    -248.13 (-0.65%)
     
  • DAX

    18,026.58
    +96.26 (+0.54%)
     
  • Hang Seng

    16,279.56
    -320.90 (-1.93%)
     
  • NIKKEI 225

    38,399.30
    -833.50 (-2.12%)
     

Nuvectis Pharma to Participate in a Fireside Chat at the 35th Annual Roth Conference

Nuvectis Pharma, Inc.
Nuvectis Pharma, Inc.

FORT LEE, NJ, March 10, 2023 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. (“Nuvectis”, “Company”), a biopharmaceutical company focused on the development of innovative precision medicines for the treatment of serious conditions of unmet medical need in oncology, today announced that Ron Bentsur, Chairman and Chief Executive Officer, will participate in a fireside chat at the 35th Annual Roth Conference.

Event

35th Annual Roth Conference

Date

March 14, 2023

Time

12:00 PM Pacific Time (3:00 PM Eastern Time)

Format

Fireside Chat

Link

https://wsw.com/webcast/roth46/nvct/1849405

About Nuvectis Pharma

Nuvectis Pharma, Inc. is a biopharmaceutical company focused on the development of innovative precision medicines for the treatment of serious conditions of unmet medical need in oncology. The Company is currently developing two drug candidates, NXP800 and NXP900. NXP800 is a clinical stage, oral small molecule currently in a Phase 1a study in patients with advanced solid tumors. NXP800 was granted Fast Track Designation by the United States Food and Drug Administration for the treatment of platinum-resistant, ARID1a-mutated, ovarian carcinoma. NXP900 is a novel, small molecule SRC/YES1 kinase inhibitor with an IND pending submission.

ADVERTISEMENT

For more information, please visit www.nuvectis.com.

Nuvectis Pharma Contact

Ron Bentsur

Chairman, Chief Executive Officer and President

rbentsur@nuvectis.com

Media Relations Contact

Christopher M. Calabrese

LifeSci Advisors

Tel: 917-680-5608

ccalabrese@lifesciadvisors.com